Checkpoint Inhibition in Myeloma: Opportunities and Challenges

Federica Costa(University of Parma), Madhav V. Dhodapkar(Emory University)

Frontiers in Immunology

September 26, 2018

10.3389/fimmu.2018.02204

Cited by 62

Related Papers

Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy

|JCI Insight|2019|167

Natural immunity to pluripotency antigen OCT4 in humans

|Proceedings of the National Academy of Sciences|2010|90

Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties

|Oncotarget|2017|30

Role of B cells in immune‐related adverse events following checkpoint blockade

|Immunological Reviews|2023|23

PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients

|Frontiers in Immunology|2021|20